The Motley Fool

Down About 47% This Year: Is Recursion Pharmaceuticals a Buy on the Dip?

Shares of Recursion Pharmaceuticals are down by about 47% from a peak the stock set this February. The company uses automation and artificial intelligence to optimize the new drug-discovery process.
MarketBeat on MSN

Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA's AI Favorite?

CompanyOverview|NASDAQ:RXRX] Recursion Pharmaceuticals' (NASDAQ: RXRX) stock price has seen a dramatic increase, not due to ...
The Motley Fool

Down 57% in 2024, Is Recursion Pharmaceuticals a Buy on the Dip?

Recursion Pharmaceuticals is a TechBio company trying to apply artificial intelligence (AI) to the new drug-discovery process. The first placebo-controlled trial results from Recursion Pharmaceuticals ...
Nasdaq

Recursion Pharmaceuticals’ (RXRX) Bold Acquisition Places it as an Industry Leader

Recursion Pharmaceuticals (RXRX), a trailblazer in AI-powered drug discovery, recently acquired its competitor, Exscientia, in a strategic move that solidifies its leading position in the industry.
Business Insider

Recursion Secures $1.6M NIH Phase 2 SBIR Grant to Identify Therapeutic Candidates for Senescence, a Key Age-Related Disease Process

SALT LAKE CITY, Nov. 8, 2018 /PRNewswire/ -- Recursion Pharmaceuticals, a biotechnology company that combines artificial intelligence (AI), experimental biology, and automation to discover and develop ...